1-Purchase-Description_2.2.24.pdf

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose: TDB Biology seeks to purchase enough HTRF reagents to detect SARS-CoV-2 nucleocapside protein in in vitro cell-based infection assays in order to conduct a high throughput screen to identify anti-SARS-CoV-2 compounds.

2. Background Information and Objective: TDB Biology group had previously collaborated with Cisbio, now a Revvity company, to develop HTRF reagents to measure the SARS-CoV-2 nucleocapsid in cell culture infection assays. In this assay an antibody combination is used to measure the levels of SARS-CoV-2 nucleocapsid, which is one of the main protein components of SARS-CoV-2. Cells are first infected with live SARS- CoV-2 or one of its variants and then as the virus replicates increasing levels of nucleocapsid can be detected by the binding of the two antibodies which produce a FRET signal. Cells treated with effective viral entry or replication inhibitors lead to a reduction in this FRET signal as less nucleocapsid is present in solution. The SARS- CoV-2 nucleocapsid assay was originally developed by NCATS in collaboration with Cisbio and now this order is needed in order to obtain enough reagents to conduct a high throughput screen.

3. Generic Name of Product: HTRF SARS-CoV-2 capsid kit

4. Purchase Description: One (1) Revvity 10,000 test HTRF SARS-CoV2 capsid kit

(Brand Name Only)

5. Salient characteristics: The specific characteristics needed for this item are:

• Use of Homogenous Time-Resolve Fluorescence compatible antibody pairs to measure concentration of SARS-CoV-2 nucleocapsid

• Antibodies pair should be labeled with Eu Cryptate and d2 fluorophore

• No wash, single step protocol for detection

• Protocol validated to work for 96 and 384 well plates

• Sensitive enough to measure SARS-CoV-2 nucleocapsid in both cultured media and lysate

6. Quantity: 1

7. Delivery Date: 30 days after receipt of order